Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cheng-Bo Han

Showing results (1-10 of 48) with videos related to

Pageof 5
Sort By:
AI Zheng = Aizheng = Chinese Journal of Cancer|December 14, 2002
[Advances in research for relationship between mitochondrial DNA and solid tumor]Cheng-bo Han, Fan Li, Yan Xin
Frontiers in Oncology|June 18, 2020
Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case ReportWei Jing, Jie-Tao Ma, Cheng-Bo Han
International Journal of Colorectal Disease|June 30, 2012
KRAS mutations in primary and metastatic colorectal cancerCheng-Bo Han, Fan Li, Jie-Tao Ma, et al.
Cancer Investigation|October 19, 2012
Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic reviewCheng-Bo Han, Fan Li, Jie-Tao Ma, et al.
Cancer Science|July 1, 2014
Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancerJie-Tao Ma, Jia-He Zheng, Cheng-Bo Han, et al.
Lung Cancer (Amsterdam, Netherlands)|February 12, 2022
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancerLe-Tian Huang, Shu-Ling Zhang, Cheng-Bo Han, et al.
Cancer Science|June 9, 2015
Response to "A meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer"Jie-Tao Ma, Cheng-Bo Han, Jia-He Zheng, et al.
Radiation Oncology (London, England)|August 25, 2020
Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysisShu-Ling Zhang, Cheng-Bo Han, Li Sun, et al.
Medical Oncology (Northwood, London, England)|January 22, 2015
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysisLi Sun, Jie-Tao Ma, Shu-Ling Zhang, et al.
World Journal of Gastroenterology|July 31, 2007
COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarrayXiao-Yun Mao, Xiao-Ge Wang, Xiao-Jun Lv, et al.
Pageof 5

Showing results (1-10 of 48) with videos related to

Sort By:
Pageof 5
AI Zheng = Aizheng = Chinese Journal of Cancer|December 14, 2002
[Advances in research for relationship between mitochondrial DNA and solid tumor]Cheng-bo Han, Fan Li, Yan Xin
Frontiers in Oncology|June 18, 2020
Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case ReportWei Jing, Jie-Tao Ma, Cheng-Bo Han
International Journal of Colorectal Disease|June 30, 2012
KRAS mutations in primary and metastatic colorectal cancerCheng-Bo Han, Fan Li, Jie-Tao Ma, et al.
Cancer Investigation|October 19, 2012
Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic reviewCheng-Bo Han, Fan Li, Jie-Tao Ma, et al.
Cancer Science|July 1, 2014
Meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancerJie-Tao Ma, Jia-He Zheng, Cheng-Bo Han, et al.
Lung Cancer (Amsterdam, Netherlands)|February 12, 2022
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancerLe-Tian Huang, Shu-Ling Zhang, Cheng-Bo Han, et al.
Cancer Science|June 9, 2015
Response to "A meta-analysis comparing higher and lower dose radiotherapy for palliation in locally advanced lung cancer"Jie-Tao Ma, Cheng-Bo Han, Jia-He Zheng, et al.
Radiation Oncology (London, England)|August 25, 2020
Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysisShu-Ling Zhang, Cheng-Bo Han, Li Sun, et al.
Medical Oncology (Northwood, London, England)|January 22, 2015
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysisLi Sun, Jie-Tao Ma, Shu-Ling Zhang, et al.
World Journal of Gastroenterology|July 31, 2007
COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarrayXiao-Yun Mao, Xiao-Ge Wang, Xiao-Jun Lv, et al.
Pageof 5